← Back to Screener
Satellos Bioscience Inc. Common Stock (MSLE)
Price$5.62
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (26W)-11.68%
Price vs S&P 500 (4W)-20.07%
VGM Score32.58
Market Capitalization$172.90M
All Metrics
Book Value / Share (Quarterly)$3.39
P/TBV (Annual)3.14x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-3.35
Price vs S&P 500 (YTD)-3.82%
EPS (TTM)$-1.81
10-Day Avg Trading Volume0.01M
EPS Excl Extra (TTM)$-1.81
EPS (Annual)$-1.70
ROI (Annual)-89.52%
Cash / Share (Quarterly)$3.36
ROA (Last FY)-78.00%
EBITD / Share (TTM)$-1.93
ROE (5Y Avg)-133.53%
Cash Flow / Share (Annual)$-0.13
P/B Ratio1.76x
P/B Ratio (Quarterly)1.66x
Net Income / Employee (Annual)$-1,381,800
ROA (TTM)-61.38%
EPS Incl Extra (Annual)$-1.70
Current Ratio (Annual)7.77x
Quick Ratio (Quarterly)15.48x
3-Month Avg Trading Volume0.03M
52-Week Price Return24.24%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.15
52-Week High$18.98
EPS Excl Extra (Annual)$-1.70
26-Week Price Return-3.76%
Quick Ratio (Annual)6.84x
13-Week Price Return-51.65%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)16.48x
Enterprise Value$54.17M
Revenue / Employee (Annual)$0
Cash / Share (Annual)$0.15
3-Month Return Std Dev98.89%
Net Income / Employee (TTM)$-1,583,300
ROE (Last FY)-89.52%
EPS Basic Excl Extra (Annual)$-1.70
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.81
ROI (TTM)-66.75%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$0.15
Price vs S&P 500 (52W)-0.12%
Year-to-Date Return3.54%
5-Day Price Return-14.32%
EPS Normalized (Annual)$-1.70
ROA (5Y Avg)-93.26%
Month-to-Date Return-18.81%
EBITD / Share (Annual)$-1.81
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-133.53%
LT Debt / Equity (Quarterly)0.04x
EPS Basic Excl Extra (TTM)$-1.81
P/TBV (Quarterly)3.14x
P/B Ratio (Annual)3.14x
Book Value / Share (Annual)$0.15
Price vs S&P 500 (13W)-59.91%
Beta1.85x
Revenue / Share (TTM)$0.00
ROE (TTM)-66.75%
52-Week Low$6.24
mGradeD
vgmGradeD
Show chart for
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.13
4.22
4.22
4.22
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
MSLESatellos Bioscience Inc. Common Stock | — | — | D | $5.62 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Satellos Bioscience is a regenerative medicine company developing novel therapeutics to stimulate and restore muscle function in severe neuromuscular disorders. The company's lead program is an oral therapeutic for Duchenne muscular dystrophy that addresses dysregulation identified as a key driver of disease progression. Satellos' approach targets the root cause of muscle degeneration rather than symptomatic relief, positioning the therapy as a potential disease-modifying treatment.